Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development
The FEBS Journal · 2024
DOI: 10.1111/febs.17203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, 2024. Verfasst von Marie Piecyk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 202 Literaturangaben. Gefördert von: Institut National Du Cancer, Ligue Contre le Cancer, Fondation ARC pour la Recherche sur le Cancer.
Abstract (Originalsprache)
Defining the mechanisms that allow cells to adapt to environmental stress is critical for understanding the progression of chronic diseases and identifying relevant drug targets. Among these, activation of the pathway controlled by the eIF2‐alpha kinase GCN2 is critical for translational and metabolic reprogramming of the cell in response to various metabolic, proteotoxic, and ribosomal stressors. However, its role has frequently been investigated through the lens of a stress pathway signaling via the eIF2α‐activating transcription factor 4 (ATF4) downstream axis, while recent advances in the field have revealed that the GCN2 pathway is more complex than previously thought. Indeed, this kinase can be activated through a variety of mechanisms, phosphorylate substrates other than eIF2α, and regulate cell proliferation in a steady state. This review presents recent findings regarding the fundamental mechanisms underlying GCN2 signaling and function, as well as the development of drugs that modulate its activity. Furthermore, by comparing the literature on GCN2's antagonistic roles in two challenging pathologies, cancer and pulmonary diseases, the benefits, and drawbacks of GCN2 targeting, particularly inhibition, are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
- Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, University Lyon I, Oullins, France.
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, France.
- Hospices Civils de Lyon, Plateforme AURAGEN, France.
- Department of Pathology, Hospices Civils de Lyon, East Hospital Group, Bron, France.
- Laboratoire CarMeN, UMR INSERM U1060/INRA U1397, University of Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
ORCID-Profile: Cedric Chaveroux
Förderung
- Institut National Du Cancer
- Ligue Contre le Cancer
- Fondation ARC pour la Recherche sur le Cancer
Zitieren
APA
Piecyk, M., Ferraro-Peyret, C., Laville, D., Perros, F., & Chaveroux, C. (2024). Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development. The FEBS Journal. https://doi.org/10.1111/febs.17203
Vancouver
Piecyk M, Ferraro-Peyret C, Laville D, Perros F, Chaveroux C. Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development. The FEBS Journal. 2024. doi:10.1111/febs.17203
BibTeX
@article{Piecyk2024,
author = {Piecyk, Marie and Ferraro-Peyret, Carole and Laville, David and Perros, Frédéric and Chaveroux, Cedric},
title = {Novel insights into the GCN2 pathway and its targeting. Therapeutic value in cancer and lessons from lung fibrosis development},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17203}
}
EUVIMED